Former COO Cortney Caudill Moves to Sell $4.3M in Halozyme Stock Following Departure
HALO sits 68% above its 52-week low of $61.225.
Summary
Former COO Cortney Caudill filed a Form 144 to sell 41,702 shares (~$4.3M) acquired via option exercise, just over a month after her departure from Halozyme.
Key Events · Ownership and Investor Activity · HALO
-
Former COO Sells $4.3M Stake
Cortney Caudill, who departed as COO on July 2, 2026, filed to sell 41,702 shares worth approximately $4.3 million, acquired via option exercise on August 11.
-
Sale Follows Record Q2 Results
The filing comes just days after Halozyme reported record Q2 revenue of $481M (+48% YoY) and royalty revenue of $308M (+50%), with the stock trading near its 52-week high.
-
Insider Conviction Questioned
A former senior executive cashing out shortly after departure, despite strong recent performance, may signal reduced confidence in the company's near-term prospects.
Analysis · HALO · Life Sciences
Just over a month after stepping down as COO, Cortney Caudill has filed to sell 41,702 shares worth approximately $4.3 million. The shares were acquired through option exercises on the same day, and the sale comes shortly after Halozyme reported record Q2 results, with the stock trading near its 52-week high. While the dollar amount is modest relative to the company's $11.6 billion market cap, the timing—a former senior executive cashing out soon after departure—raises a flag about insider conviction, especially given the recent blowout quarter.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HALO was trading at $102.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $61.23 to $104.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.